148 related articles for article (PubMed ID: 38200609)
1. TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.
Zhang Y; Huang Z; Li K; Xie G; Feng Y; Wang Z; Li N; Liu R; Ding Y; Wang J; Yang J; Jia Z
J Exp Clin Cancer Res; 2024 Jan; 43(1):16. PubMed ID: 38200609
[TBL] [Abstract][Full Text] [Related]
2. Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
Vummidi Giridhar P; Williams K; VonHandorf AP; Deford PL; Kasper S
Cancer Res; 2019 Mar; 79(6):1124-1137. PubMed ID: 30626627
[TBL] [Abstract][Full Text] [Related]
3. TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.
Singh R; Karri D; Shen H; Shao J; Dasgupta S; Huang S; Edwards DP; Ittmann MM; O'Malley BW; Yi P
J Clin Invest; 2018 Jul; 128(7):3129-3143. PubMed ID: 29715200
[TBL] [Abstract][Full Text] [Related]
4. lncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/MDM2 axis.
Liang D; Tian C; Zhang X
Mol Med Rep; 2022 Jul; 26(1):. PubMed ID: 35616155
[TBL] [Abstract][Full Text] [Related]
5. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
7. DNA damage-induced activation of ATM promotes β-TRCP-mediated Mdm2 ubiquitination and destruction.
Wang Z; Inuzuka H; Zhong J; Fukushima H; Wan L; Liu P; Wei W
Oncotarget; 2012 Sep; 3(9):1026-35. PubMed ID: 22976441
[TBL] [Abstract][Full Text] [Related]
8. S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy.
Qi M; Yi X; Yue B; Huang M; Zhou S; Xiong J
Breast Cancer Res; 2023 May; 25(1):55. PubMed ID: 37217945
[TBL] [Abstract][Full Text] [Related]
9. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
10. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
[TBL] [Abstract][Full Text] [Related]
11. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract][Full Text] [Related]
12. GSG2 facilitates the progression of human breast cancer through MDM2-mediated ubiquitination of E2F1.
Tang Y; Dai G; Yang Y; Liu H
J Transl Med; 2023 Aug; 21(1):523. PubMed ID: 37537694
[TBL] [Abstract][Full Text] [Related]
13. p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2).
Liu T; Li Y; Gu H; Zhu G; Li J; Cao L; Li F
J Biol Chem; 2013 Feb; 288(5):3359-69. PubMed ID: 23132866
[TBL] [Abstract][Full Text] [Related]
14. MDM2 E3 ubiquitin ligase mediates UT-A1 urea transporter ubiquitination and degradation.
Chen G; Huang H; Fröhlich O; Yang Y; Klein JD; Price SR; Sands JM
Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1528-34. PubMed ID: 18784257
[TBL] [Abstract][Full Text] [Related]
15. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis.
Sehat B; Andersson S; Girnita L; Larsson O
Cancer Res; 2008 Jul; 68(14):5669-77. PubMed ID: 18632619
[TBL] [Abstract][Full Text] [Related]
16. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
[TBL] [Abstract][Full Text] [Related]
17. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
Jung CR; Lim JH; Choi Y; Kim DG; Kang KJ; Noh SM; Im DS
J Clin Invest; 2010 Dec; 120(12):4493-506. PubMed ID: 21060154
[TBL] [Abstract][Full Text] [Related]
18. TAGLN Is Downregulated by TRAF6-Mediated Proteasomal Degradation in Prostate Cancer Cells.
Wen F; Sun X; Sun C; Dong Z; Jia G; Bao W; Yu H; Yang C
Mol Cancer Res; 2021 Jul; 19(7):1113-1122. PubMed ID: 33771884
[TBL] [Abstract][Full Text] [Related]
19. Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells.
Jin H; Lee K; Kim YH; Oh HK; Maeng YI; Kim TH; Suh DS; Bae J
Oncogene; 2016 Sep; 35(39):5106-18. PubMed ID: 26973248
[TBL] [Abstract][Full Text] [Related]
20. The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.
Sparks A; Dayal S; Das J; Robertson P; Menendez S; Saville MK
Oncogene; 2014 Sep; 33(38):4685-96. PubMed ID: 24121268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
